Corcept initiates study of nenocorilant with nivolumab in advanced solid tumors
Corcept Therapeutics is conducting a dose-finding study of nenocorilant combined with nivolumab in advanced solid malignancies.
Company
Pharmaceutical intelligence for Corcept Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.